Novartis
NEWS
It was another busy week in clinical trial news. Here’s a look.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
Researchers with the Georgia Institute of Technology recently published work that describes several new approaches to improving CAR-T, particularly for solid tumors.
The companies will use their funds to support the development of their lead assets and advance their pipelines.
The FDA-initiated partial hold on Novartis’ gene therapy trial for spinal muscular atrophy has been lifted recently. Here’s everything you need to know about it.
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.
The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
JOBS
IN THE PRESS